Jaswal Gaurav, Benipal Raja, Bhatty Seema G, Garg Pardeep, Kang Manraj S
Department of Radiation Oncology, Dr. Prem Super Speciality and Cancer Hospital, Panipat, Haryana, India.
Department of Radiation Oncology, Government Medical College, Patiala, Punjab, India.
J Pharm Bioallied Sci. 2023 Jul;15(Suppl 2):S1062-S1064. doi: 10.4103/jpbs.jpbs_221_23. Epub 2023 Jul 11.
Two HDR brachytherapy regimes were compared, 9.5 Gray per fraction for two fractions and 7.5 Gray per fraction for three fractions.
A total of 80 patients with histologically evident squamous cell carcinoma cervix were taken in the current research after randomization. Radiotherapy dose delivered was 50 Gray/25#/5 weeks with concomitant chemotherapy with weekly cisplatin 35 mg/m. Following external chemoradiation, patients were randomized into two arms. In Arm A, 40 patients were given high dose rate (HDR) brachytherapy of weekly 7.5 Gray in three fractions over 3 weeks. In Arm B, 40 patients were given high dose rate (HDR) brachytherapy of weekly 9.5 Gray in two fractions over 2 weeks. BED and LQED had been calculated, and the evaluation of response and consequences was examined.
In Arm A, BED to point A was 99.38 ± 0.00 and EQD2 to point A was 82.81 ± 0.00. In Arm B, BED to point A was 97.05 ± 0.00 and EQD2 to point A was 80.89 ± 0.00. With respect to rectum in Arm A, BED rectum was 108.66 ± 11.43 and EQD2 rectum was 65.07 ± 6.84. In Arm B, BED rectum was 107 ± 10.83 and EQD2 rectum was 64.21 ± 6.49. Similarly in Arm A, BED bladder was 107.86 ± 10.23 and EQD2 bladder was 64.59 ± 6.13. In arm B, BED bladder was 104.14 ± 10.79 and EQD2 bladder was 62.36 ± 6.46.
In a follow-up of 6 months, no statistical significance in terms of local control as well as complications rates in both the arms. Our research demonstrates that two fractions of HDR are comparable with three fractions of HDR.
比较了两种高剂量率近距离放射治疗方案，即每次分割9.5戈瑞，分两次进行；以及每次分割7.5戈瑞，分三次进行。
本研究共纳入80例经组织学确诊为宫颈鳞状细胞癌的患者，随机分组。放疗剂量为50戈瑞/25次/5周，同时每周给予顺铂35毫克/平方米进行化疗。外照射化疗后，患者被随机分为两组。A组40例患者接受高剂量率（HDR）近距离放射治疗，每周7.5戈瑞，分三次，共3周。B组40例患者接受高剂量率（HDR）近距离放射治疗，每周9.5戈瑞，分两次，共2周。计算了生物等效剂量（BED）和线性二次模型等效剂量（LQED），并对反应和结果进行了评估。
A组中，A点的BED为99.38±0.00，A点的等效均匀剂量（EQD2）为82.81±0.00。B组中，A点的BED为97.05±0.00，A点的EQD2为80.89±0.00。关于A组的直肠，直肠的BED为108.66±11.43，直肠的EQD2为65.07±6.84。B组中，直肠的BED为107±10.83，直肠的EQD2为64.21±6.49。同样，A组中膀胱的BED为107.86±10.23，膀胱的EQD2为64.59±6.13。B组中，膀胱的BED为104.14±10.79，膀胱的EQD2为62.36±6.46。
在6个月的随访中，两组在局部控制和并发症发生率方面无统计学意义。我们的研究表明，两次分割的高剂量率近距离放射治疗与三次分割的高剂量率近距离放射治疗效果相当。
